Neumora Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | 29.3% | 29.3% | -30.7% |
| FY2023 | -50.3% | -50.3% | -47.5% |
| FY2024 | -84.9% | -84.9% | -76.9% |
| FY2025 | -228.1% | -149.6% | -124.0% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | 29.3% | 29.3% | -30.7% |
| FY2023 | -50.3% | -50.3% | -47.5% |
| FY2024 | -84.9% | -84.9% | -76.9% |
| FY2025 | -228.1% | -149.6% | -124.0% |